MB
Maria R. Baer
Highly rated in
29
conditions
Highly rated in
29
conditions
Check Dr. Maria R. Baer's experience treating your condition:
About Dr. Maria R. Baer

Maria Baer is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Baer has been practicing medicine for over 44 years and is highly rated in 29 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. She is licensed to treat patients in Maryland. Baer is currently accepting new patients.

Her clinical research consists of co-authoring 197 peer reviewed articles and participating in 19 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Maria R. Baer it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Maria R. Baer accepts the following insurance:

  •  Ambetter
  •  CareFirst

Call to see if your plan is accepted.
Locations
22 S Greene St, Baltimore, MD 21201
Other Locations
10 N Greene St, Baltimore, MD 21201
Background & Education
Graduate Institution
Johns Hopkins University School Of Medicine, 1979
Specialties
Hematology Oncology
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
UM Shore Medical Center At Easton
University Of Maryland Medical Center
Baltimore VA Medical Center
Languages Spoken
English
French
Spanish
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


19 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Multicenter Phase 1/2 Study of Combination Therapy w/ DNA Methyltransferase Inhibitor Decitabine & Poly ADP Ribose Polymerase Inhibitor Talazoparib for Untreated AML in Adults Unfit for Cytotoxic Chemotherapy or R/R AML
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
View 15 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors